Who
Peter Heerma
EVP, Chief Commercial Officer
Company insider
Files Form 4 as: EVP, Chief Commercial Officer, Travere Therapeutics.
In numbers
- Trades disclosed
- 112
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $38.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Oct 2019
- Last trade
- 17 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $186K8,282 at $22.40 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $539K8,282 at $65.07 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,282 at $0.00 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,282 at $0.00 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $186K8,282 at $22.40 | filing |
| 17 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $539K8,282 at $65.07 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $476K17,717 at $26.88 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.9M93,604 at $63.25 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.0M79,113 at $63.65 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —55,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,717 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —55,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,717 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.1M100,000 at $11.25 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $850K55,000 at $15.46 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.1M100,000 at $11.25 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $850K55,000 at $15.46 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $476K17,717 at $26.88 | filing |
News
No headline names them, or the companies they trade most, lately.